This study showed that ribose can be used safely in a dose of both 9 g and 18 g per day during periods of 3 months in a patient with genetically confirmed dystroglycanopathy due to an FKRP mutation. The gene discussed is FKRP; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.